Search

Displaying results 2681 - 2690 of 10000 in total
  1. Drug

    Givosiran

    go.drugbank.com/drugs/DB15066
    Approved

    [L10202] It is manufactured by Alnylam Pharmaceuticals and was first approved for use in the United States in November 2019 for the treatment of adults with acute hepatic porphyria, a genetic disorder … Givosiran is a small interfering RNA (siRNA) directed towards 5-aminolevulinic acid synthase, a critical enzyme in the heme biosynthesis pathway.

  2. Drug

    Vibrio cholerae CVD 103-HgR strain live antigen

    go.drugbank.com/drugs/DB14443
    ApprovedInvestigational

    prevention to become available in the U.S. … [A244494] Vaxchora was later approved by the European Commission in April 2020.[L39729] It is indicated for individuals aged two years and older.[L12801]

  3. Drug

    Human vaccinia virus immune globulin

    go.drugbank.com/drugs/DB14112
    ApprovedInvestigational

    Nevertheless, VIG by virtue of the way it is produced is a poorly characterized and highly variable human product that is only available in very limited quantities - all factors that may intervene with … The IgG fraction is purified by the anion-exchange column chromatography method and the solution is solvent/detergent-treated to sterilize the compound [A33814].

  4. Drug

    Estetrol

    go.drugbank.com/drugs/DB12235
    ApprovedInvestigational

    Estetrol is the first new estrogen introduced to the USA in over 50 years and is the first approved estetrol product in the world. … [L33179] In Canada, Nextstellis was approved for use in March 2021; it was developed by Mithra and is marketed by Searchlight Pharma.[L33209]

  5. Drug

    Repotrectinib

    go.drugbank.com/drugs/DB16826
    ApprovedInvestigational

    This approval is based on favorable results from the TRIDENT-1 study, where the objective response rate was 79% in TKI-naive patients and 38% in TKI-pretreated patients respectively.[L48741] … Repotrectinib is a next-generation tyrosine kinase inhibitor (TKI) specifically designed to address resistance in the treatment of non-small cell lung cancer (NSCLC), specifically due to mutations in the

  6. Drug

    Riluzole

    go.drugbank.com/drugs/DB00740
    ApprovedInvestigational

    Riluzole is marketed as Rilutek by Sanofi. … A glutamate antagonist (receptors, glutamate) used as an anticonvulsant (anticonvulsants) and to prolong the survival of patients with amyotrophic lateral sclerosis.

    Categories: Compounds used in a research, industrial, or household setting
  7. Drug

    Dihydrocodeine

    go.drugbank.com/drugs/DB01551
    ApprovedIllicit

    It was marketed in 1911. … It is semi-synthetic, and was developed in Germany in 1908 during an international search to find a more effective antitussive agent to help reduce the spread of airborne infectious diseases such as tuburculosis

    Products: PARACODIN N, PARACODIN N TROPFEN
  8. Drug

    Copper histidinate

    go.drugbank.com/drugs/DB32041
    Approved

    [A275383,T903] In patients with the disease, defects in this transporter lead to the entrapment of copper in the intestinal lining and a subsequent inability to absorb it into the bloodstream, resulting … in severe systemic copper deficiency.

  9. Drug

    Ethoxzolamide

    go.drugbank.com/drugs/DB00311
    ApprovedWithdrawn

    Ethoxzolamide is a sulfonamide used as diuretic and in glaucoma. It inhibits carbonic anhydrase activity in proximal renal tubules to decrease reabsorption of water, sodium, potassium, bicarbonate.

  10. Drug

    Olutasidenib

    go.drugbank.com/drugs/DB16267
    ApprovedInvestigational

    in 2-hydroxyglutarate (2-HG), a metabolite that participates in tumerogenesis. … Olutasidenib (FT-2102) is a selective and potent isocitrate dehydrogenase-1 (IDH1) inhibitor approved by the FDA in December 2022.